# HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

> **NCT07137637** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Hangzhou Polymed Biopharmaceuticals, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)

## Interventions

- **DRUG:** HPB-092 tablet

## Key facts

- **NCT ID:** NCT07137637
- **Lead sponsor:** Hangzhou Polymed Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2027-09-14
- **Final completion:** 2027-12-14
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07137637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07137637, "HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07137637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*